Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSP90AA1 | P07900 | 2/20 | 0.46 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.45 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.45 |
| ▸ | NOS1 | P29475 | 8/20 | 0.44 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.42 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.42 |
| ▸ | ATR | Q13535 | 2/20 | 0.42 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | DHFR | P00374 | 1/20 | 0.40 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3762339 | 0.93 | NOS1 (0.44) | NOS1ALDH1A1KDM4EDHFRADORA2A | |
| SCHEMBL3766518 | 0.86 | MGMT (0.47) | NOS1TSHR | |
| SCHEMBL3755480 | 0.86 | NOS1 (0.40) | PTPN1NOS1DHFR | |
| SCHEMBL3761952 | 0.86 | NOS1 (0.45) | NOS1CHRNA7DHFR | |
| SCHEMBL3760633 | 0.85 | MAOB (0.44) | NOS1GAADHFRADORA2A | |
| SCHEMBL3769692 | 0.85 | NOS1 (0.44) | PTPN1NOS1ALDH1A1ATR | |
| SCHEMBL3766675 | 0.85 | NOS1 (0.46) | NOS1DHFR | |
| SCHEMBL3760785 | 0.85 | CHRNA7 (0.44) | NOS1CHRNA7 | |
| SCHEMBL3752631 | 0.84 | NOS1 (0.43) | NOS1HSD17B10ALDH1A1ATRKDM4E | |
| SCHEMBL3760969 | 0.84 | L3MBTL1 (0.47) | HSP90AA1HSP90AB1PTPN1NOS1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7276506-B2 | Immunosuppressive effects of pteridine derivatives | 4 AZA BIOSCIENCE NV (BE) | 2007-10-02 | — | — | US | claimed |
| EP-1663244-B1 | PTERIDINE DERIVATIVES FOR THE TREATMENT OF TNF-ALPHA-RELATED DISEASES. | 4 AZA IP NV (BE) | 2007-08-15 | — | — | EP | claimed |
| US-20070004721-A1 | Pteridine derivatives for the treatment of septic shock and tnf-a-related diseases | 4 AZA BIOSCIENCE NV (BE) | 2007-01-04 | — | — | US | claimed |
| EP-1663244-A2 | PTERIDINE DERIVATIVES FOR THE TREATMENT OF SEPTIC SHOCK AND TNF-ALPHA-RELATED DISEASES. | 4 AZA Bioscience nv (BE) | 2006-06-07 | — | — | EP | claimed |
| EP-1658081-A2 | IMMUNOSUPPRESSIVE EFFECTS OF PTERIDINE DERIVATIVES | 4 AZA Bioscience nv (BE) | 2006-05-24 | — | — | EP | claimed |
| WO-2005025574-A2 | PTERIDINE DERIVATIVES FOR THE TREATMENT OF SEPTIC SHOCK AND TNF-α-RELATED DISEASES. | 4 AZA BIOSCIENCE NV (BE) | 2005-03-24 | — | — | WO | claimed |
| WO-2005021003-A2 | IMMUNOSUPPRESSIVE EFFECTS OF PTERIDINE DERIVATIVES | 4 AZA BIOSCIENCE NV (BE) | 2005-03-10 | — | — | WO | claimed |
| US-20040077859-A1 | Immunosuppressive effects of pteridine derivatives | 4 AZA BIOSCIENCE NV (BE) | 2004-04-22 | — | — | US | claimed |
| US-7501513-B2 | Immunosuppressive effects of pteridine derivatives | 4 AZA BIOSCIENCE NV (BE) | 2009-03-10 | — | — | US | disclosed |
| US-7276506-B2 | Immunosuppressive effects of pteridine derivatives | 4 AZA BIOSCIENCE NV (BE) | 2007-10-02 | — | — | US | disclosed |
| EP-1663244-B1 | PTERIDINE DERIVATIVES FOR THE TREATMENT OF TNF-ALPHA-RELATED DISEASES. | 4 AZA IP NV (BE) | 2007-08-15 | — | — | EP | disclosed |
| US-20070004721-A1 | Pteridine derivatives for the treatment of septic shock and tnf-a-related diseases | 4 AZA BIOSCIENCE NV (BE) | 2007-01-04 | — | — | US | disclosed |
| US-20060287314-A1 | Immunosuppressive effects of pteridine derivatives | 4 AZA BIOSCIENCE NV (BE) | 2006-12-21 | — | — | US | disclosed |
| US-20060189620-A1 | Immunosuppressive effects of pteridine derivatives | 4 AZA BIOSCIENCE NV (BE) | 2006-08-24 | — | — | US | disclosed |
| EP-1663244-A2 | PTERIDINE DERIVATIVES FOR THE TREATMENT OF SEPTIC SHOCK AND TNF-ALPHA-RELATED DISEASES. | 4 AZA Bioscience nv (BE) | 2006-06-07 | — | — | EP | disclosed |
| EP-1658081-A2 | IMMUNOSUPPRESSIVE EFFECTS OF PTERIDINE DERIVATIVES | 4 AZA Bioscience nv (BE) | 2006-05-24 | — | — | EP | disclosed |
| WO-2005025574-A2 | PTERIDINE DERIVATIVES FOR THE TREATMENT OF SEPTIC SHOCK AND TNF-α-RELATED DISEASES. | 4 AZA BIOSCIENCE NV (BE) | 2005-03-24 | — | — | WO | disclosed |
| WO-2005021003-A2 | IMMUNOSUPPRESSIVE EFFECTS OF PTERIDINE DERIVATIVES | 4 AZA BIOSCIENCE NV (BE) | 2005-03-10 | — | — | WO | disclosed |
| US-20040077859-A1 | Immunosuppressive effects of pteridine derivatives | 4 AZA BIOSCIENCE NV (BE) | 2004-04-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040077859-A1 | Immunosuppressive effects of pteridine derivatives | TPMT, NFATC1, MALT1 | HSP90AA1 3911/4885HSP90AB1 3422/4885PTPN1 424/4885 |
| US-20060287314-A1 | Immunosuppressive effects of pteridine derivatives | TPMT, NFATC1, MALT1 | HSP90AA1 4097/4885HSP90AB1 3680/4885PTPN1 439/4885 |
| US-20060189620-A1 | Immunosuppressive effects of pteridine derivatives | TPMT, NFATC1, MALT1 | HSP90AA1 3911/4885HSP90AB1 3422/4885PTPN1 424/4885 |
| US-20070004721-A1 | Pteridine derivatives for the treatment of septic shock and tnf-a-related diseases | TNF, TNFRSF1A, TLR4 | HSP90AA1 354/4885HSP90AB1 373/4885PTPN1 2790/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.